Breast cancer cells resistant to doxorubicin express high levels of TRPC5, which enhances the expression of P-glycoprotein via the Ca2+-dependent transcription factor NFATc3 (Ma et al., 2012). Here, TRPC5 is linked to breast carcinoma.